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Abstract
Background: Colorectal cancer represents the most common malignancy of the gastrointestinal tract. Owing to
differences in dietary habits and lifestyle, this neoplasm is more common in industrialized countries than in
developing ones. Evidence from a wide range of sources supports the assumption that the link between diet and
colorectal cancer may be due to an imbalance of the intestinal microflora.
Discussion: Probiotic bacteria are live microorganisms that, when administered in adequate amounts, confer a
healthy benefit on the host, and they have been investigated for their protective anti-tumor effects. In vivo and
molecular studies have displayed encouraging findings that support a role of probiotics in colorectal cancer
prevention.
Summary: Several mechanisms could explain the preventive action of probiotics against colorectal cancer onset.
They include: alteration of the intestinal microflora; inactivation of cancerogenic compounds; competition with
putrefactive and pathogenic microbiota; improvement of the host’s immune response; anti-proliferative effects via
regulation of apoptosis and cell differentiation; fermentation of undigested food; inhibition of tyrosine kinase
signaling pathways.
Background
Colorectal cancer [CRC] is one of the major health pro-
blems in the world, representing the most common malig-
nancy of the gastrointestinal [GI] tract. CRC is more
frequent in industrialized countries than in developing
ones with a four times higher incidence [1]. Differences in
dietary habits and lifestyle rather than racial factors may
explain this gap as it has been demonstrated by studies on
migrants. The diet is likely to play a key role in the patho-
genesis of CRC. Epidemiological studies have shown that
the consumption of red meat and animal fat is associated
with an increased risk for CRC development [2], whereas
a diet rich in fruits and vegetables appears to be protective
against CRC [3]. Evidence from a wide range of sources
supports the assumption that the link between diet and
CRC may be due to an imbalance of the intestinal micro-
flora [4]. At birth, the GI tract is colonized by microbes
and remains the home for several populations of microor-
ganisms throughout the life of the host. The ‘normal’ gut
microflora consists of bacterial species with morphologi-
cal, physiological and genetic features that let it to colonize
and multiply under particular conditions at certain sites,
coexist with other colonizing microorganisms and compe-
titively inhibit the growth of pathogenic bacteria. Never-
theless, some environmental factors such as diet and drugs
can alter the composition of the resident microbiota, with
consequent dysmicrobia and negative implications for the
health of the individual. The colonic microflora is very
rich and dominated by strict anaerobic bacteria such as
Bacteroides spp., Fusobacterium spp., Clostridium spp, and
many others [5]. Probiotic bacteria may be defined as ‘live
microorganisms which when administered in adequate
amounts confer a health benefit on the host’ [6], and they
most frequently belong to the lactic acid bacteria [LAB]
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category, such as Lactobacillus spp. and Bifidobacterium
spp. LAB are widely available, for instance, in yogurts and
other functional foods such as cheese, fermented and
unfermented milks, juices, smoothies, cereal, nutrition
bars and infant/toddler formula [7]. A number of studies
in animal models and in human population have demon-
strated that the consumption of probiotics is effective in
various medical conditions such as lactose intolerance,
antibiotic-induced diarrhea, gastroenteritis, constipation,
and genitourinary tract infections [8]. Moreover, accumu-
lating evidence suggests that the ingestion of probiotics
may be able to play a preventive role in the onset of CRC
[4]. This observation seems to be very interesting as it
would make possible an effective strategy for CRC primary
prevention. This review is merely intended at providing an
outline of the possible mechanisms whereby probiotics
may exert their beneficial effects for CRC prevention. We
have given greater emphasis on those novel mechanisms,
such as the inhibition of tyrosine kinase signaling path-
ways and anti-proliferative effects, that have not been
thoroughly discussed yet.
Discussion
Mechanisms of CRC prevention exerted by probiotics
Despite the great number of studies in the literature, the
precise mechanisms by which probiotics may prevent
CRC still remain not perfectly clear. However, it is con-
ceivable that they include: alteration of the intestinal
microflora; inactivation of cancerogenic compounds;
competition with putrefactive and pathogenic microbiota;
improvement of the host’s immune response; anti-prolif-
erative effects via regulation of apoptosis and cell differ-
entiation; fermentation of undigested food; inhibition of
tyrosine kinase signaling pathways. The coadministration
of probiotics with prebiotics [which are defined as ‘selec-
tively fermented ingredients that allow specific changes,
both in the composition and/or activity in the gastroin-
testinal microflora that confer benefits upon host well-
being and health’ [9], the so-called synbiotics, can
increase the effectiveness of these anti-cancer mechan-
isms [10,11]. Moreover, the acidification of pH, although
not considered as a distinct mechanism of action, is an
intrinsic and fundamental feature whereby many probio-
tics carry out their metabolic activities [12,13]. These
potential mechanisms will be discussed individually now.
Alteration of the intestinal microflora metabolism
Glucuronide conjugation is one of the major metabolic
processes occurring in the liver. It is critical to metabolize
hormones, and also to inactivate toxic and carcinogenic
compounds of endogenous and exogenous origin. The
conjugation with glucuronic acid results in polar metabo-
lites that are efficiently eliminated in the bile [14]. The
deconjugation of these glucuronides in the intestine by
bacterial b-glucuronidase leads to the release of aglycones
that are potentially carcinogenic substances [15]. There
are other fecal bacterial enzymes, including azoreductase
and nitroreductase, which catalyze the liberation of pro-
carcinogenic substances in the intestine [16,17]. The
alteration of the intestinal metabolism by modulating the
activity of these bacterial enzymes may be one of the pos-
sible mechanisms by which probiotics may reduce the risk
for the onset of CRC [18]. It has been demonstrated that a
yogurt feeding can reduce the levels of b-glucuronidase
and nitroreductase contained in the large intestine of mice
bearing colon cancer [19]. Goldin and Gordbach [18]
reported a decrease in fecal bacterial enzyme activity after
a Lactobacillus acidophilus feeding in animal models. The
same authors [20] recruited 21 young healthy subjects for
a study aimed at investigating the effect of L. acidophilus
oral supplements on the enzyme activity of b-glucuroni-
dase, nitroreductase and azoreductase. Both two strains of
L. acidophilus used in the study [N-2 and NCFM] caused
a significant decrease in the activities of the three fecal
enzymes after a ten-days lactobacilli feeding. Having
stopped the bacterial feedings, fecal enzyme levels
returned to normal after four weeks, suggesting that con-
tinuous ingestion of these organisms is required for these
enzyme effects to be maintained in the microflora. How-
ever, apparently ambiguous or discordant results have
been shown by most human studies designed to investi-
gate the effects of probiotics supplementation on fecal
enzyme bacterial activity [21-26]. For example, Marteau et
al. [24] reported a decrease only in nitroreductase activity
after a three weeks-period of ingesting a fermented dairy
product containing L. acidophilus, Bifidobacterium bifi-
dum, and mesophilic cultures [Streptococcus lactis and
Streptococcus cremoris] while b-glucuronidase and azore-
ductase activities did not change. Indeed, these findings
suggest that the capability of modulating fecal enzymes
bacteria activity is a strain-specific characteristic for pro-
biotics. The duration and amount of probiotic intake are
other considerable factors. Moreover, the degree of rela-
tionship between the ability of probiotics to influence the
bacterial metabolism and the prevention of CRC has to be
better clarified.
Inactivation of cancerogenic compounds
A meta-analysis of 15 prospective studies showed a rela-
tive risk of developing CRC of 1.28 for subjects with a
higher consumption of red meat, when compared with
people who eat red meat in lower quantities [2]. Several
hypotheses have been proposed to explain this relation-
ship. Heterocyclic aromatic amines [HCA], formed as a
result of cooking meat at high temperatures, are among
the substances called into question [27,28]. Intestinal
Uccello et al. BMC Surgery 2012, 12(Suppl 1):S35
http://www.biomedcentral.com/1471-2482/12/S1/S35
Page 2 of 8
microbiota can activate HCA to their active derivatives





quinoline [MeIQ], and 2-amino-3,8-dimethylimidazo[4,5-
f]quinoxaline [MeIQx] [29,30]. Such powerful mutagenic
substances may act with the colonic mucosa, causing
tumorigenic mutations [30]. LAB and other commensal
bacteria have been found to bind or metabolize several
carcinogens, including HCA and N-nitroso compounds.
Binding and/or degradation well correlates with the reduc-
tion in mutagenicity observed after exposure of HCA to
the bacterial strains [31-33]. According to the literature,
the binding or degradation of HCA by probiotics could be
one of the main mechanisms of removing carcinogens out
of the human body. Orrhage et al. [32] studied the in vitro
capacity of some LAB to bind mutagenic HCA formed
during the cooking of protein-rich food. The binding of
the mutagens Trp-P-2, PhIP, IQ and MeIQx by the bacter-
ial strains was analyzed by HPLC. Trp-P-2 was almost
completely and irreversibly bound while the binding of
PhIP, a major mutagen in the western diet, reached about
50%. IQ and MeIQx were slightly less well bound. Sreeku-
mar and Hosono [34,35] demonstrated that different
strains of Lactobacillus gasseri and Bifidobacterium
longum strongly bound Trp-P-1 and Trp-P-2. Oral supple-
mentation with L. acidophilus NCFB1748 and B. longum
BB536 decreased the bioavailability of Trp-P-2 in the GI
tract and other several tissues in mice [36]. Cell fractions
of L. acidophilus and Bifidobacterium spp. have been
found to bind Trp-P-1 and decrease its genotoxicity [37].
Most data suggest that the binding of mutagens could be
due to the bacterial cell wall [32,37,38] though the anti-
mutagenic effect of Lactobacillus plantarum KLAB21 is
mediated by three extracellular glycoproteins [39]. Challa
et al. [40] demonstrated that a B. longum and lactulose
feeding in rats significantly increased the activity of colonic
glutathione S-transferase, which is one of the Phase II
enzymes involved in the detoxification of toxic metabolites
and carcinogens, and suppressed azoxymethane [AOM]-
induced colonic aberrant crypt foci [ACF] that are preneo-
plastic markers. More recently, Lactobacillus casei
DN 114001 has been shown to grow and survive in the
presence of IQ, MelQx and PhIP and to decrease their
concentrations [12].The probiotic ability to bind or meta-
bolize toxic compounds depends on pH and other physi-
cochemical conditions [12,32,33]. All these results indicate
that the detoxification of cooked food mutagenic com-
pounds, commonly found in the western meat-rich diet,
may be one of the main mechanisms by which LAB antag-
onize the onset of CRC.
Competition with putrefactive and pathogenic microbiota
The GI tract, particularly the colon, is very heavily popu-
lated with bacteria. Although most gut bacteria are
benign, some species are pathogenic and may be involved
in the onset of acute and chronic disorders, including
CRC [41]. It is established that a diet rich in animal fat
stimulates the growth of secondary bile salt-producing
bacteria and further studies have shown that secondary
bile salts are cytotoxic and carcinogenic [42,43]. A diet
rich in red meat also facilitates the growth of sulfate-
reducing bacteria producing hydrogen sulfide which
experimentally is known to be genotoxic [44-46]. Putre-
factive intestinal microbiota such as Bacteroides spp. and
Clostridium spp. have been implicated in the pathogen-
esis of CRC [47] while numerous LAB have been shown
to possess cancer-preventing attributes [31]. Rafter et al.
[48] found that the synbiotic combination of a specific
oligofructose-enriched inulin with probiotics on the fecal
flora of polyp and colon cancer patients caused an
increase in the number of some groups of LAB [Bifido-
bacterium in both groups and Lactobacillus in polyp
patients], whereas the number of Clostridium perfringens
in polyp patients significantly decreased. The consump-
tion of probiotics alone have also proved effectiveness to
cause changes in GI microflora, with a significant reduc-
tion of fecal putrefactive bacteria, such as coliforms, and
an increase of LAB [49,50]. These effects may be
mediated by adherence to enterocytes and the pH lower-
ing [13,51]. Furthermore, O’Mahony et al. reported that
the enteric flora modification in interleukin-10 [IL-10]
knockout mice by probiotic Lactobacillus salivarius
UCC118 resulted in a reduced prevalence of colon cancer
[49]. Thus, probiotics may counteract CRC development
also through a mechanism of competition with patho-
genic intestinal microbiota.
Improvement of the host’s immune response
The immune system plays an important role in the con-
trol of tumor promotion and progression. The close
interaction of several elements of the immune system,
such as antigen-presenting cells [APCs], and different
subsets of T cells, B cells and natural killer [NK] cells, is
critical for the generation of an effective anti-tumour
immune response [52]. Besides other potential effects in
the prevention of cancer, probiotics have been suggested
to enhance the mucosal and system immune response
[53]. In 1981, Yokokura [54] screened 26 strains of 14
different species of LAB for in vivo anti-tumor activities
against a transplantable mouse sarcoma, and noticed that
some of these strains had potent anti-tumor effects.
Among them, especially Lactobacillus casei Shirota [LcS]
showed a high potential. Since such strain is not directly
cytotoxic to tumor cells in vitro, it has been postulated
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that its anti-tumor effects may be mediated by the
enhancement of the host’s immune system [55]. This
hypothesis has elicited further investigations on the anti-
tumor and immunoregulatory action of LcS in various
experimental models [56-58]. Oral administration of LcS
has exhibited beneficial effects in both humans and ani-
mals as well as anti-tumor activity against human bladder
cancer cells in clinical trials [59,60]. LcS has been shown
to possess powerful anti-tumor and anti-metastatic
effects on transplantable tumor cells and to suppress che-
mically-induced carcinogenesis in rodents. In particular,
It has been noted that the intrapleural administration of
LcS into tumor-bearing mice has induced the production
of several cytokines, such as Interferon-g [IFN-g], inter-
leukin-b [IL-1b] and tumor necrosis factor-a [TNF-a],
leading to the inhibition of tumor growth and to an
increased survival [58,61]. After LcS is ingested by the
host, it is incorporated into M cells in Peyer’s patches
and digested to form active components. In Peyer’s
patches, macrophages or dendritic cells [DCs], after pha-
gocytosing LcS, become able to produce several cyto-
kines, especially TNF-a. Then, the components of LcS
digested in Peyer’s patches are recognized through toll-
like receptor 2 in APCs, and lead to the production of
several cytokines that stimulate different responses in
host immune cells [62]. Lcs has also exhibited a strong
anti-tumor effect in mice by regulating the host immune
response in a 3-methylcholanthrene [MC]-induced carci-
nogenesis model [63] that has been used to induce many
tumors, including colon cancer model [64,65]. An LcS
oral feeding of mice is likely to counteract MC-induced
tumorigenesis by ameliorating the host immune
responses which have been disrupted during MC carci-
nogenesis. A possible mechanism of carcinogenesis pre-
vention is the proliferation and activation of NK cells
[66]. NK cells are large granular lymphocytes derived
from bone marrow, and have a critical role in immune
surveillance against tumor development [67]. Other pos-
sible effector cells that may respond to LcS and other
probiotics are DCs [62,68]: they represent important
types of cells involved in the presentation of several anti-
gens and in the production of cytokines [69]. In addition,
oral administration of LcS has been shown to stimulate
type 1 helper T cells, activate the cellular immune sys-
tem, and inhibit the incidence of tumors and IgE produc-
tion in mice [70]. More recently, it has been reported
that LcS has suppressed murine tumorigenesis with
potent elicitation to produce interleukin-12 [IL-12] by
bone marrow-derived cells in vitro [71] and to inhibit of
interleukin-6 [IL-6] production in the colonic mucosa
[72]. In numerous studies, other probiotic strains have
shown remarkable immunoprotective properties through
the increase of specific and non-specific mechanisms that
have anti-tumor effects. For instance, Lee et al. [73]
reported that the administration for four weeks of
L. acidophilus SNUL, L. casei YIT9029 and B. longum
HY8001, for instance, increased the survival rate of mice
injected with tumor cells. The increase of survival was
correlated with an increase in cellular immunity as
reflected by an augmentation in the number of total
T cells, NK cells and MHC class II+ cells, and CD4−CD8+
T cells in flow cytometry analysis. These findings suggest
that the treatment with probiotics has the potential to
prevent CRC by modulation of the host’s immune sys-
tem, specifically cellular immune responses.
Anti-proliferative effects via regulation of apoptosis and
cell differentiation
Apoptosis is a genetically determined mode of cell death
playing a key role in the regulation of cell numbers. In
many types of cancer, a reduced ability to trigger apoptosis
is an important pathogenetic event that is accompanied by
alteration of control processes of cell proliferation [74].
The regulation of cell survival and death with molecules
acting on the apoptotic process can have a huge chemo-
preventive and therapeutic potential [75]. There is much
evidence that probiotics can have a role in the regulation
of cell proliferation and apoptosis which are potentially
crucial mechanisms in the prevention of CRC. Iyer et al.
[76] found that Lactobacillus reuteri suppressed TNF-
induced NF-B activation in a dose and time-dependent
manner. L. reuteri may regulate cell proliferation by pro-
moting apoptosis of activated immune cells via inhibition
of IkBa ubiquitination and enhancing pro-apoptotic mito-
gen activated protein kinase [MAPK] signaling. The pro-
biotic mixture VSL#3 has been reported to suppress the
COX-2 expression in Colo320 and SW480 intestinal
epithelial cells [77]. The expression of COX-2 is increased
in colorectal tumors [78], and this elevation can protect
intestinal epithelial cells from apoptosis [79,80]. Recently,
rodent studies have demonstrated that the synbiotic com-
bination of resistant starch and Bifidobacterium lactis has
exerted a pro-apoptotic action in response to the carcino-
gen, AOM [10,81]. Other studies have postulated that pro-
biotics possess CRC-protective effects by altering the
differentiation process of tumor cells. Using a cultured
human colon cancer cell line [HT-29], Baricault et al. [82]
studied the effect of fermented milks on colon cancer cell
proliferation and growth. Milks were fermented by one of
the following bacterial populations: Lactobacillus helveti-
cus, Bifidobacterium, L. acidophilus or a mix of Streptococ-
cus thermophilus and Lactobacillus bulgaricus. After
HT-29 cells were added to the fermented milk, only
L. acidophilus was found to have no effects on both cell
growth and differentiation while the three other bacterial
strains induced a significant, although variable, reduction
in the growth rate of HT-29 cells, which resulted in a
10-50% decrease in the cell number at steady-state.
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Concomitantly, the specific activities of dipeptidyl pepti-
dase IV, which is a sensitive and specific marker of HT-29
cell differentiation, and those of three other brush border
enzymes [sucrase, aminopeptidase N and alkaline phos-
phatase] were significantly increased, thus suggesting that
these cells may have entered a differentiation process.
Moreover, the combination of Bifidobacterium breve
R0070 + Lactobacillus lactis R1058 + oligoalternan inhib-
ited the proliferation of HT-29 cells in absence of cytotoxic
effect [83]. This could be explained by the induction from
an undifferentiated phenotype to a more differentiated
one. In fact, the results showed that cancerous HT-29
cells treated with the synbiotic, when compared with the
differentiated ones, reached the same rate expression of
intestinal alkaline phosphatase, a biomarker of colic differ-
entiation [84]. Singh et al. [85] demonstrated that a dietary
administration in rats of lyophilized cultures of B. longum
resulted in a significant suppression of colon tumor inci-
dence and tumor multiplicity, and it also reduced the
tumor volume. Analyses on intermediate biomarkers also
revealed that the ingestion of B. longum inhibited AOM-
induced cell proliferation through a reduction in ornithine
decarboxylase [ODC] activity. ODC is involved in the bio-
synthesis of polyamines that cause cell proliferation and
differentiation of the colonic mucosa [86]. According to
these data, an improved understanding of LAB-mediated
effects on apoptosis and differentiation signalling pathways
may facilitate the development of future probiotics-based
regimens for the prevention of CRC.
Fermentation of undigested food
The bacterial transformation of dietary components in the
intestinal lumen may be associated with the production of
cancer-preventive agents and may therefore be another
mechanism whereby probiotics can influence CRC risk.
The bacterial fermentation of indigestible carbohydrates
generates short-chain fatty acids [SCFA] and gas; while
the gas is eliminated in the feces, SCFA [mainly acetate,
propionate and butyrate] represent nutrients and growth
signals for the intestinal mucosa and may play a role in
CRC prevention [87]. They reduce, for instance, the con-
centration of secondary bile salts. Butyrate, that is the
most widely studied of these SCFA, is a preferred energy
source for colonocytes and is likely to promote a normal
phenotype in these cells. In CRC cell lines, butyrate
enhances cellular differentiation and reduces proliferation
[88,89]. In human studies, butyrate and the associated low-
ering of luminal pH are correlated with a reduced risk of
CRC [90,91]. A specific strain [MDT-1] of the ruminal
bacterium Butyrivibrio fibrisolvens has been evaluated for
use as a probiotic to prevent CRC cancer since it produces
high amounts of butyrate [92]. Using a mouse model of
colon cancer, the administration of MDT-1 has reduced
the number of ACF and the percentage of mice with an
increased proportion of ACF. Furthermore, the human
probiotic Propionibacterium spp. has been shown to kill
CRC cells through apoptosis in vitro via its metabolites,
the SCFA, acetate and propionate [93,94]. However, syn-
biotics would be more active than probiotics alone in
increasing the production of SCFA and consequently pro-
tect against CRC onset [10,95]. A possible explanation is
that the interaction of the immunomodulating properties
of probiotic bacteria and butyrate, which is more produced
via fermentation of prebiotics, results in an upregulation of
apoptosis [10,11]. In addition to SCFA, probiotics are
involved in the production of another group of fatty acids,
termed conjugated linoleic acids [CLAs]. These are a
group of isomers of linoleic acid that have been shown to
exert numerous health benefits, including anti-inflamma-
tory and anti-carcinogenic effects [96,97]. In rodent stu-
dies CLA has been shown to reduce the incidence of
colonic tumors [98,99]. Using animal models, Ewaschuk
et al. [100] demonstrated that the probiotic strains in the
mixture VSL#3 are able to convert linoleic acid into CLA,
inducing the upregulation of PPARg, a reduction in colo-
nic tumor cells viability, and the induction of apoptosis.
These studies support a role for supplemental probiotics
as a strategy for preventing CRC by fermentation of indi-
gestible food, but further investigations are needed.
Inhibition of tyrosine kinase signaling pathways
Signaling pathways are represented by a series of biochem-
ical events whereby a cell communicates with the extracel-
lular environment. Signaling pathways are activated by
receptors or cytoplasmic proteins with tyrosine kinase
activity and play a critical role in carcinogenesis [101].
Saccharomyces boulardii [Sb] is a safety probiotic agent
used to prevent or treat a wide variety of human GI disor-
ders [102,103]. It has been reported that Sb acts through
modulation of the host signaling pathways that regulate
the intestinal mucosal inflammatory response. In particu-
lar, Sb down-regulates MAPK signaling pathways
[104,105] that are located downstream of many growth-
factor receptors, including the epidermal growth factor
receptor [EGFR]. The EGF receptor family consists of four
members: ErbB1/EGFR/HER1, ErbB2/HER2/Neu, ErbB3/
HER-3 and ErbB4/HER-4 that are important for cancer
development [106]. Chen et al. [107] wanted to examine
the effects of Sb on tumor development in ApcMin mice,
an animal model used for quantitative and mechanistic
studies of the induction of intestinal tumors [108]. Sb pre-
vented cancer cell colony formation, reduced EGF-
mediated cell proliferation, and increased apoptosis. Both
in vitro and in vivo effects were consistent with inhibition
of the EGFR and Akt pathways. Furthermore, a laboratory
study by Ma et al. [109] demonstrated that the probiotic
Bacillus polyfermenticus suppressed colon cancer cells
growth in vitro and colon cancer tumor growth in vivo.
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Bacillus polyfermenticus exerted its anticancer effect
through the reduction of ErbB2 and ErbB3 and their
downstream signaling molecules E2F-1 and cyclin D1.
Thus, in addition to the other anti-tumorigenic effects,
probiotics may inhibit EGFR and other tyrosine kinase sig-
naling pathways and thereby may also serve a novel thera-
peutic or prophylactic role in intestinal malignancies.
Conclusions
Although a wide range of studies have brought to grow-
ing remarkable findings in recent years, it has not still
been possible to obtain conclusive clinical evidence sup-
porting the role of probiotics in CRC prophylaxis. Since
CRC is an impractical endpoint in terms of numbers of
subjects, cost, study duration and ethical considerations,
probiotic intervention studies often use recurrence of
preneoplastic lesions or intermediate biomarkers of can-
cer as an endpoint [110,111]. Several mechanisms could
explain the preventive action of probiotics against CRC
onset. All of the CRC-preventing mechanisms previously
discussed are supported in varying degrees from in vitro
and animal model studies, some of them even from
human clinical studies. We are not still able to deter-
mine which mechanisms are most effective. Most likely
distinct strains of probiotics operate with specific
mechanisms. Further investigations are strongly required
in order to establish the impact of each mechanism and
the real usefulness of probiotics in CRC prevention.
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